Clinical Considerations for <em>RET</em> Fusion–Positive NSCLC

Listen to lung cancer experts Joshua Bauml, MD, a molecular oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, including testing for RET fusions, using new selective RET inhibitors in these patients, and the importance of interdisciplinary communication.